Company Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 11:59:32 2024-03-27 am EDT 5-day change 1st Jan Change
2,084 DKK -1.98% Intraday chart for Genmab A/S +2.51% -3.29%

Business Summary

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (83.2%);

- income from research and development (12.4%);

- other (4.4%): primarily income from partnership agreement.

At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

Number of employees: 2,204

Sales per Business

DKK in Million2022Weight2023Weight Delta
Antibody Therapeutics
100.0 %
14,595 100.0 % 16,474 100.0 % +12.87%

Sales per region

DKK in Million2022Weight2023Weight Delta
Denmark
97.4 %
14,595 100.0 % 16,053 97.4 % +9.99%
United States
2.3 %
0 0.0 % 380 2.3 % -
Japan
0.2 %
0 0.0 % 41 0.2 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 63 98-12-31
Director of Finance/CFO 46 06-12-31
Chief Operating Officer 53 20-03-22
Chief Tech/Sci/R&D Officer 51 16-12-31
Public Communications Contact - 19-03-10
Human Resources Officer 46 -
Corporate Officer/Principal 67 17-02-08
Corporate Officer/Principal 71 00-12-31
General Counsel 63 01-12-31

Members of the board

Members of the board TitleAgeSince
Chairman 63 16-12-31
Director/Board Member 73 03-10-31
Director/Board Member 63 15-12-31
Director/Board Member 59 22-03-28
Director/Board Member 57 14-12-31
Director/Board Member 73 14-12-31
Director/Board Member 51 19-03-28
Director/Board Member 49 21-12-31
Director/Board Member 50 21-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,122,964 65,365,889 ( 98.86 %) 744,170 ( 1.125 %) 98.86 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
4.899 %
3,237,113 4.899 % 907 M kr
Global Opportunities (GO) Capital Asset Management BV
3.558 %
2,351,225 3.558 % 659 M kr
ATP Fondsmaeglerselskab A/S
2.320 %
1,532,909 2.320 % 429 M kr
GENMAB A/S
1.425 %
941,528 1.425 % 264 M kr
600,497 0.9088 % 168 M kr
Industriens Pensionsforsikring A/S
0.7800 %
515,356 0.7800 % 144 M kr
Nykredit Bank A/S (Investment Management)
0.4853 %
320,668 0.4853 % 90 M kr
State Street Global Advisors Ltd.
0.2605 %
172,154 0.2605 % 48 M kr
Danske Bank A/S (Investment Management)
0.2348 %
155,169 0.2348 % 43 M kr
Sampension Administrationsselskab A/S
0.1746 %
115,344 0.1746 % 32 M kr
NameEquities%Valuation
AllianceBernstein LP
2.363 %
15,614,510 2.363 % 434 M kr
BlackRock Advisors LLC
0.6620 %
4,374,250 0.6620 % 121 M kr
Capital Research & Management Co. (International Investors)
0.6141 %
4,057,922 0.6141 % 113 M kr
Harding Loevner LP
0.4979 %
3,289,895 0.4979 % 91 M kr
Wellington Management Co. LLP
0.3586 %
2,369,331 0.3586 % 66 M kr
RBC Trust Co. Delaware Ltd.
0.2371 %
1,566,907 0.2371 % 44 M kr
Renaissance Technologies LLC
0.2262 %
1,494,800 0.2262 % 42 M kr
First Trust Advisors LP
0.1922 %
1,270,095 0.1922 % 35 M kr
Morgan Stanley Investment Management, Inc.
0.1648 %
1,089,097 0.1648 % 30 M kr
Wells Fargo Bank NA
0.1623 %
1,072,144 0.1623 % 30 M kr

Holdings

NameEquities%Valuation
941,528 1.42% 263,802,249 $

Company contact information

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com
address Genmab A/S(GMAB)